10:11 AM
 | 
Jun 15, 2017
 |  BC Week In Review  |  Clinical News  |  Regulatory

Y-mabs gets FDA breakthrough therapy designation for neuroblastoma candidate burtomab

Y-mabs Therapeutics Inc. (New York, N.Y.) said FDA granted breakthrough therapy designation to burtomab (I-8H9) to treat pediatric patients with relapsed or refractory neuroblastoma with CNS or leptomeningeal metastasis.

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >